AGENNIX AG

Agennix AG is a publicly listed biopharmaceutical company. The Company’s clinical development programs include oral lactoferrin alfa; a topical gel form of lactoferrin and RGB-286638, a multi-targeted kinase inhibitor.

Agennix’s registered seat is in Heidelberg, Germany. The Company’s site of operation is in Princeton, New Jersey.